Silexion Therapeutics price to book ratio SLXN

Market value divided by the book value of the company's net assets, since 2025.

Today, Oct 23, 2026: 23.9×
Peer median: 0.6×

Silexion Therapeutics' price to book ratio is 23.9× as of Oct 23, 2026.

The median for 10 biotech stocks of a similar size is 0.6×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	23.9×	0.3×	55.0×
2025	1.0×	1.0×	44.6×

Against its peers

Companies in Biotechnology nearest Silexion Therapeutics' size, closest first, today.

Company	Price to book ratio
SLXNSilexion Therapeutics	23.9×
CRISCuris	0.2×
CLDICalidi Biotherapeutics	0.5×
VIVSVivoSim Labs, INC.	n/m
PMCBPharmaCyte Biotech	0.1×
LIMNLiminatus Pharma	13.1×
AIMAIM ImmunoTech	0.6×
CELZCreative Medical Technology	0.6×
SNTISenti Biosciences	n/m
INABIN8BIO	0.6×
INTSIntensity Therapeutics	1.2×
Peer median	0.6×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Silexion Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.